Vital Living Names Dr. Yadu Moharir as Director of Quality Control

PHOENIX, July 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- Vital Living, Inc. (VTLV) announced today it has named, effective June 2005, Dr. Yadu Moharir as Director of Quality Control for all of the company's product lines.

In the new position, Dr. Moharir will be responsible for establishing quality standards for Vital Living's growing line of products, currently including Greensfirst(R), Dream Protein(R), and Complete Essentials(R). Dr. Moharir will be based in Phoenix, AZ and will report to Stuart Benson, chief executive officer of Vital Living.

With more than 25 years of industry experience, Dr. Moharir brings critical expertise in the creation and analysis of unique scientific products. Since November 2001, Dr. Moharir is president of Nutritional Consultants Unlimited. Prior to that, he was Vice President of Scientific Affairs for Olympian Labs. From 1997-1999, Dr. Moharir served as Director of Research and Development at Nature's Way. He was also a teaching faculty member at the McMaster Medical College in Canada.

Commenting on the appointment, Benson said, "Dr. Moharir brings to Vital Living a strong track record in the analysis and evaluation of nutritional products and supplements. His expertise as an analytical chemist and experience in conducting clinical trials on finished formulations adds tremendous value to our company."

Since 1995, Dr. Moharir has developed more than 20 analytical methods for herbal products and vitamin supplements. He is also a published author with 17 publications attributed to his name, including various trade articles, and three manuscripts under preparation. Dr. Moharir received a Ph.D. in Chemistry in 1975 from Nagpur University, India, and has done extensive research in natural products and analytical chemistry in U.S. and Canada.

"We are pleased Dr. Moharir has agreed to join Vital Living as Director of Quality Control. His long history of accomplishments and influence in the scientific field will be a key asset. We look forward to his valuable contributions as we continue to grow our company," concluded Benson.

About Vital Living, Inc.

Headquartered in Phoenix, Vital Living develops or licenses nutraceuticals and markets them for distribution through physicians, medical groups, chiropractic offices and retail outlets. Vital Living develops and tests its nutraceuticals in collaboration with leading medical experts in the nutraceuticals field and has designed them to be incorporated by physicians into a standard physician-patient program in which patients supplement doctor- prescribed pharmaceuticals with its nutraceuticals.

Vital Living is developing unique, safe and naturally derived nutritional products, utilizing advanced drug-delivery technologies, including the Geomatrix(TM) technology through its affiliation with SkyePharma PLC. The Geomatrix(TM) technology has been provided exclusively for Vital Living's pharmaceutical development in China, and the development of nutraceuticals on a global basis. For more information on the company, please visit

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements in this press release include improved net cash flow, and the success of the Company's cost-cutting efforts, corporate restructuring initiative, the Company's positioning for future growth, the strength of the Company's products, the ability of the Company's management, and the Company's future performance. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the ability of the Company to manage the development of the three pharmaceutical products, regulatory approval of the pharmaceutical products, and the ultimate success of the products. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.